The FDA recently announced that an ultrasound (U/S) device for breast cancer screening– the somo-v ABUS–has been approved for use in women with dense breasts.
The FDA recently announced that an ultrasound (U/S) device for breast cancer screening– the somo-v ABUS–has been approved for use in women with dense breasts.
Made by U-Systems of Sunnyvale, Calif, the product is to be used along with standard mammography in women with a negative mammogram and no breast cancer symptoms. It has a specially shaped transducer that automatically scans the entire breast in about 1 minute, producing several images for review, according to the FDA.
In a trial conducted by U-Systems, radiologists examined mammograms from 200 asymptomatic women with dense breasts, with and without supplementary U/S images from the somo-v ABUS device. Results indicated that use of the U/S images increased breast cancer detection by about 30%. Approximately 4% of results in the trial were false-positives.
Because previous breast intervention such as surgery or biopsy might alter the appearance of breast tissue on U/S, the agency said that women who had previously had such interventions would not generally be eligible for screening with the device.
For clinicians and technologists who plan to use the device, the FDA will require that U-Systems conduct training. The company must also distribute a manual that describes quality control tests that users should perform regularly.
Read other articles in this issue of Special Delivery.
Adverse maternal outcomes after uterine conservation in placenta accreta spectrum
May 9th 2024A review of 5 studies reveals a significant 1 in 4 incidence of adverse maternal outcomes following uterine conservation in patients with placenta accreta spectrum, underlining the importance of expert multidisciplinary care.
Read More
Barriers in seeking pelvic floor disorder treatment among ethnic minorities
May 8th 2024A recent shed light on how ethnic minority groups perceive pelvic floor disorders, highlighting barriers to treatment seeking and the importance of raising awareness about available treatment options.
Read More
Variations found in testosterone therapy for women with HSDD
May 7th 2024Dive into the intricate landscape of testosterone therapy prescriptions among women with hypoactive sexual desire disorder, revealing diverse patterns in duration, administration routes, and estrogen co-administration.
Read More